Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers -- Ignore unavailable to you. Want to Upgrade?

To: Paul Kelly who wrote (570)	11/6/1998 12:22:00 PM
From: Doug Meetmer	Read Replies (1) \| Respond to of 961

All I can say is that if 20% of the patients who took the drug seroconverted, that is pretty amazing. Of course, we don't have access to all the data to see the controls or the side effects, but chronic Hepatitis B is by and large untreatable and so if 20% of patients seroconverted, that implies they were cured. The impact on global health costs could be huge, since chronic Hep B leads to cirrhosis, which comes with a host of problems such as gastrointestinal bleeding, infection, death...